GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (XSWX:NOVNEE) » Definitions » EV-to-FCF

Novartis AG (XSWX:NOVNEE) EV-to-FCF

: 18.30 (As of Today)
View and export this data going back to 2008. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Novartis AG's Enterprise Value is CHF189,852 Mil. Novartis AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was CHF10,374 Mil. Therefore, Novartis AG's EV-to-FCF for today is 18.30.

The historical rank and industry rank for Novartis AG's EV-to-FCF or its related term are showing as below:

XSWX:NOVNEE' s EV-to-FCF Range Over the Past 10 Years
Min: 14.26   Med: 18.39   Max: 23.57
Current: 18.3

During the past 13 years, the highest EV-to-FCF of Novartis AG was 23.57. The lowest was 14.26. And the median was 18.39.

XSWX:NOVNEE's EV-to-FCF is ranked better than
57.89% of 513 companies
in the Drug Manufacturers industry
Industry Median: 21.66 vs XSWX:NOVNEE: 18.30

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), Novartis AG's stock price is CHF87.53. Novartis AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF6.275. Therefore, Novartis AG's PE Ratio for today is 13.95.


Novartis AG EV-to-FCF Historical Data

The historical data trend for Novartis AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.24 20.61 15.00 15.81 18.20

Novartis AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.81 14.15 15.83 15.90 18.20

Competitive Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG EV-to-FCF Distribution

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Novartis AG's EV-to-FCF falls into.



Novartis AG EV-to-FCF Calculation

Novartis AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=189852.040/10373.881
=18.30

Novartis AG's current Enterprise Value is CHF189,852 Mil.
Novartis AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF10,374 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novartis AG  (XSWX:NOVNEE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Novartis AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=87.53/6.275
=13.95

Novartis AG's share price for today is CHF87.53.
Novartis AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF6.275.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Novartis AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Novartis AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (XSWX:NOVNEE) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (XSWX:NOVNEE) Headlines

No Headlines